Literature DB >> 9805596

Weight changes during clozapine treatment.

D Briffa1, T Meehan.   

Abstract

OBJECTIVE: The aim of this study was to assess the prevalence and magnitude of weight changes pre- and post-clozapine and to explore the ability of demographic and clinical factors to predict weight gain at 12 months post-clozapine.
METHOD: Weight changes in a sample of 51 patients were assessed at 3 months pre-clozapine, at baseline, and at 3 and 12 months post-clozapine. In addition, demographic data and information concerning changes in appetite and activity level at 3 months was gathered and used to predict weight gain at 12 months.
RESULTS: Seventy percent of patients gained an average of 7.5 kg (10.6% increase in baseline body weight) over the 12-month period. Although post-clozapine weight gain for the total group was significant at 12 months, weight gain for the female subsample (n = 16) did not reach significance at either the 3 or 12 month assessments. The only factors associated with marked weight gain (> 15% increase) at 12 months were increased food intake early in treatment and having gained weight at 3 months.
CONCLUSION: Clozapine treatment was found to be associated with significant weight gain in patients prescribed clozapine, especially male patients. Considering the long-term health risks associated with excess weight gain, health professionals can play an important role in educating clients about the potential for weight gain with clozapine treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9805596     DOI: 10.3109/00048679809113128

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  11 in total

Review 1.  Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Bodyweight gain with atypical antipsychotics. A comparative review.

Authors:  T Wetterling
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

Review 3.  Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.

Authors:  J M Russell; J A Mackell
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.

Authors:  Emmanuel Stip; Ovidiu V Lungu
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

5.  Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Authors:  Nima Davoodi; Mikhail Kalinichev; Sergei A Korneev; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

Review 6.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Weight gain, obesity, and psychotropic prescribing.

Authors:  Nikhil Nihalani; Thomas L Schwartz; Umar A Siddiqui; James L Megna
Journal:  J Obes       Date:  2011-01-17

8.  Comparative effectiveness of antipsychotic drugs in schizophrenia.

Authors:  T S Stroup; J A Lieberman; M S Swartz; J P McEvoy
Journal:  Dialogues Clin Neurosci       Date:  2000-12       Impact factor: 5.986

9.  Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.

Authors:  E Stip; O V Lungu; K Anselmo; G Letourneau; A Mendrek; B Stip; O Lipp; P Lalonde; L A Bentaleb
Journal:  Transl Psychiatry       Date:  2012-06-19       Impact factor: 6.222

Review 10.  Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review.

Authors:  Othman Sentissi; Jacques Epelbaum; Jean-Pierre Olié; Marie-France Poirier
Journal:  Schizophr Bull       Date:  2007-12-28       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.